Actively Recruiting
Investigation of Cardioversion Versus Therapeutic Ablation for Persistent AF (ORBICA-AF)
Led by Barts & The London NHS Trust · Updated on 2025-09-03
208
Participants Needed
1
Research Sites
175 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main aim of the research is to investigate whether patients undergoing pulmonary vein isolation with catheter ablation for persistent atrial fibrillation (AF) will have lower rates of AF recurrence than those treated by DC cardioversion without an ablation procedure.
CONDITIONS
Official Title
Investigation of Cardioversion Versus Therapeutic Ablation for Persistent AF (ORBICA-AF)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Ability to give informed consent
- Age 18-85 years
- Persistent atrial fibrillation lasting more than 7 days with total duration less than 2 years as documented
- Patients being considered for cardioversion
You will not qualify if you...
- Creatinine clearance (eGFR) less than 30 mL/min
- Contraindication or inability to take anticoagulation
- Uncontrolled hypertension
- Contraindication for catheter ablation
- Body mass index (BMI) over 40
- Patients in persistent AF with more than one previous cardioversion
- Established diagnosis of hypertrophic cardiomyopathy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Barts Heart Centre
London, United Kingdom, EC1A 7BE
Actively Recruiting
Research Team
M
Malcolm Finlay, FRCP PhD
CONTACT
V
Vijayabharathy Kanthasamy, MRCP
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here